The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
about
Ribavirin plus interferon versus interferon for chronic hepatitis CCancer history and other personal factors affect quality of life in patients with hepatitis C.Extrahepatic manifestations of chronic hepatitis C virus infectionThe changing landscape of hepatitis C virus therapy: focus on interferon-free treatmentImpact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional OutcomesValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceCerebral dysfunction in chronic hepatitis C infection.Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQHealth-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment.Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyPortraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.Clinical utility of pharmacogenomics in the management of hepatitis C.Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysisHepatitis C advances in antiviral therapy: what is accepted treatment now?Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin.Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.The burden of hepatitis C in the United States.Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada).Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.Hepatitis C: What is the nature of the problem?Therapeutic modalities in hepatitis C: challenges and development.Health-related quality of life in patients with chronic hepatitis C and advanced fibrosisChronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural EgyptEstimation of utilities for chronic hepatitis C from SF-36 scores.Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in EgyptHealth-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study.Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?Definition and management of anemia in patients infected with hepatitis C virus.Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in TaiwanQuality of life in hepatitis C.Hepatitis C screening: getting it right.The effect of hepatitis C virus infection on health-related quality of life in prisoners.Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C.Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.
P2860
Q24240879-EF76DA3C-6026-481B-99D2-82681EB3B192Q24814090-23A308E5-09F1-4E53-932E-68EC6540EF58Q26767084-7E7521B7-889C-4318-8EAD-952C8AA13B61Q26795559-48FA4304-C33B-438B-AF98-D9F29C2A1F20Q27487975-718969FD-5B18-430C-8CB4-18BE2D679042Q28072257-8AFC0DBD-6EC0-48C2-BA63-5C5BE6F8853DQ30773516-625DED16-6A9B-4C7A-BCDB-F71AE169333BQ33430951-94572352-5A8D-4D97-94EE-32E35B9BFB24Q33813860-CD0CC47D-04CC-45D8-908F-F82A8D6853C2Q33953930-BE5248FA-83B6-4AB1-8B73-FB624A51DD6CQ34072683-A879306C-7CE2-4515-8E9F-AF3F45B9D8DFQ34146792-7868E9C3-284E-493E-BDC8-FEE145483DB5Q34348710-2587BC94-3E14-49C0-A9ED-887FEE3EE083Q34464613-83F90538-BAB5-44B4-93EE-A62A127F3325Q34533176-4ADDD8BB-F8AA-40DA-93C9-98F2D5C37C5EQ34619384-AA6B1DE5-01FC-475F-AB40-4083C89309ACQ34681541-AEE0644C-976F-4CB0-B969-E47DD81ACE59Q34799386-140C878A-81C9-43D4-A0D0-34774AFFF2F7Q34984035-4DF32A18-2F1B-495B-B6A9-9AEDE183FDD5Q35453012-951FC75E-31CF-464D-938F-A411DAC341C5Q35768976-081A1B05-48AA-4383-B39A-0B16396E91BEQ35882845-0DE0BB7D-EE02-43E6-9D75-D4BEF90D0BEAQ36011951-836E2079-C6C1-4469-92C7-6BDB8A7E2231Q36015711-201B37E2-1C4C-4A55-9A64-07D9208D819AQ36020207-14327879-D175-44A8-976B-40F964935F97Q36060018-D26368EF-D8B2-40EC-98CF-0A74ACCD7379Q36192046-453B7C7B-6052-4210-9755-D224F9338E4EQ36256411-148EED1B-6A87-4419-944C-AFCF5A14823DQ36310606-E75CCE25-98FB-4DCE-AC2D-5D2BA940F465Q36335752-4566C60B-6C52-439F-8479-C300FA73FDEDQ36418455-6A32AB81-783E-45C3-8AF8-692B9AFCE05CQ36455842-2630A25B-FB68-402E-AA6E-CBD3094D2632Q36497183-C19C938C-8E8E-40DA-BB75-680474026D0FQ36566758-B503F558-B79D-437C-9D7F-10DDF6A8E66EQ36575211-62415DED-E799-4742-BDCD-E274B609E6EDQ36856011-2C481EB9-C368-4520-B756-38782B18BA8FQ36883317-DD19372D-EB99-4650-9809-DC5B1D869FFAQ37116816-59878D59-BD91-4E02-B700-1573EE49AB30Q37254462-D9B547AE-9025-4D6B-BD71-A30DEA54EB1EQ37536874-5F072436-E0FE-41F0-BF7B-10328482B424
P2860
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The effects of interferon alph ...... of life and work productivity.
@ast
The effects of interferon alph ...... of life and work productivity.
@en
type
label
The effects of interferon alph ...... of life and work productivity.
@ast
The effects of interferon alph ...... of life and work productivity.
@en
prefLabel
The effects of interferon alph ...... of life and work productivity.
@ast
The effects of interferon alph ...... of life and work productivity.
@en
P2093
P1476
The effects of interferon alph ...... of life and work productivity.
@en
P2093
Hepatitis Interventional Therapy Group
J G McHutchison
J K Albrecht
M S Bayliss
P304
P356
10.1016/S0168-8278(00)00026-X
P577
2001-01-01T00:00:00Z